Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Number of DPC Hospitals to Increase to 718 in FY2008
March 10, 2008
- PMDA Announces Draft Operation and System Optimization Plan
March 10, 2008
- Range of Public Healthcare Benefits to Become Center of Discussions
March 10, 2008
- REGULATORY NEWS IN BRIEF
March 10, 2008
- Takashi Kodama Elected JPA President
March 10, 2008
- Kitasato Univ.-Harvard School of Public Health Symposium
March 10, 2008
- Ethical Drugs Market Exceeds \8 Trillion in 2007: IMS
March 10, 2008
- Kyowa Hakko Licenses Antibody for Cancer Treatment
March 10, 2008
- Daiichi Sankyo Places Top Priority on 5 Projects
March 3, 2008
- Sanofi-aventis Enters into Antibody Agreements with Dyax
March 3, 2008
- Blood Pressure Management Not Adequate: Pfizer Survey
March 3, 2008
- Toyobo Expands Contract Manufacturing Business
March 3, 2008
- NCCHD-Led NW to Participate in Multinational Clinical Trials
March 3, 2008
- Sales of Plavix Up 5.5-Fold in Japan: sanofi-aventis
March 3, 2008
- Development Delayed for 16 Unapproved Drugs
March 3, 2008
- Competition Heats Up on the Market for Statins
March 3, 2008
- Introduce GCP Auditor Certification System: Prof. Horie
March 3, 2008
- Makers Should Propose Invoice Prices That Reflect Market Prices: Mr Hamada of Toho
March 3, 2008
- Korosho to Survey Measures Taken Overseas to Ensure Safety of Research Using iPS Cells
March 3, 2008
- Iberica Ready to Undertake PI Studies Simultaneously in both Japanese and Americans
March 3, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…